The reduction in price target by Wedbush from $245 to $213, while maintaining a Neutral rating, suggests a cautious outlook on Biogen's stock performance in the short term. This adjustment reflects analyst Laura Chico's revised expectations, which could influence investor sentiment and potentially lead to a decrease in Biogen's stock price.